IL2 and neoplasm: Combination of local RT and intratumoral immunocytokine (IT-IC), consisting of anti-GD2 antibody linked to interleukin 2 (IL-2), achieved an in situ vaccine effect, where immunomodulating treatments of the tumor induce activation of local and then systemic T cell responses against tumor antigens.